
Rajnikant B. Patel
Examiner (ID: 11242, Phone: (571)272-2082 , Office: P/2838 )
| Most Active Art Unit | 2838 |
| Art Unit(s) | 3621, 2836, 2111, 2838, 2839 |
| Total Applications | 2545 |
| Issued Applications | 2301 |
| Pending Applications | 64 |
| Abandoned Applications | 184 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10820480
[patent_doc_number] => 20160166644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-16
[patent_title] => 'MODULATING APOPTOSIS'
[patent_app_type] => utility
[patent_app_number] => 15/049953
[patent_app_country] => US
[patent_app_date] => 2016-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 16957
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15049953
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/049953 | Protection against apoptosis from ionizing radiation | Feb 21, 2016 | Issued |
Array
(
[id] => 12185457
[patent_doc_number] => 20180044393
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-15
[patent_title] => 'OREXIN-B POLYPEPTIDES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/551334
[patent_app_country] => US
[patent_app_date] => 2016-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 20961
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15551334
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/551334 | OREXIN-B POLYPEPTIDES AND USES THEREOF | Feb 17, 2016 | Abandoned |
Array
(
[id] => 12152870
[patent_doc_number] => 20180024135
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-25
[patent_title] => 'MULTIFUNCTIONAL MAGNETO-POLYMERIC NANOSYSTEMS FOR RAPID TARGETING, ISOLATION, DETECTION AND SIMULTANEOUS IMAGING OF CIRCULATING TUMOR CELLS'
[patent_app_type] => utility
[patent_app_number] => 15/551865
[patent_app_country] => US
[patent_app_date] => 2016-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 3463
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15551865
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/551865 | MULTIFUNCTIONAL MAGNETO-POLYMERIC NANOSYSTEMS FOR RAPID TARGETING, ISOLATION, DETECTION AND SIMULTANEOUS IMAGING OF CIRCULATING TUMOR CELLS | Feb 14, 2016 | Abandoned |
Array
(
[id] => 12160314
[patent_doc_number] => 20180031579
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-02-01
[patent_title] => 'METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH MALIGNANT HEMATOLOGICAL DISEASE TO CHEMOTHERAPY TREATMENT AND METHODS OF TREATMENT OF SUCH DISEASE'
[patent_app_type] => utility
[patent_app_number] => 15/550394
[patent_app_country] => US
[patent_app_date] => 2016-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 17897
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15550394
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/550394 | METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH MALIGNANT HEMATOLOGICAL DISEASE TO CHEMOTHERAPY TREATMENT AND METHODS OF TREATMENT OF SUCH DISEASE | Feb 10, 2016 | Abandoned |
Array
(
[id] => 10813738
[patent_doc_number] => 20160159899
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'TREATMENT OF CANCER WITH ANTI-IL-1 ALPHA ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 15/013469
[patent_app_country] => US
[patent_app_date] => 2016-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 6601
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15013469
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/013469 | TREATMENT OF CANCER WITH ANTI-IL-1 ALPHA ANTIBODIES | Feb 1, 2016 | Abandoned |
Array
(
[id] => 12139482
[patent_doc_number] => 20180017565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-18
[patent_title] => 'PLASMA BIOMARKER FOR OVARIAN CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/546223
[patent_app_country] => US
[patent_app_date] => 2016-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 13061
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546223
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/546223 | PLASMA BIOMARKER FOR OVARIAN CANCER | Jan 26, 2016 | Abandoned |
Array
(
[id] => 12139481
[patent_doc_number] => 20180017564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-18
[patent_title] => 'METHOD AND KIT FOR THE DETECTION OF BILIARY TRACT CANCER (AS AMENDED)'
[patent_app_type] => utility
[patent_app_number] => 15/546178
[patent_app_country] => US
[patent_app_date] => 2016-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 19748
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546178
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/546178 | Method and kit for the detection of biliary tract cancer | Jan 24, 2016 | Issued |
Array
(
[id] => 13761193
[patent_doc_number] => 10172925
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-01-08
[patent_title] => Uses of partial peptides of survivin and variations thereof
[patent_app_type] => utility
[patent_app_number] => 15/003959
[patent_app_country] => US
[patent_app_date] => 2016-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 7791
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 231
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15003959
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/003959 | Uses of partial peptides of survivin and variations thereof | Jan 21, 2016 | Issued |
Array
(
[id] => 12127513
[patent_doc_number] => 20180011098
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-11
[patent_title] => 'METHODS AND KITS FOR ANALYSIS OF HMGB1 ISOFORMS'
[patent_app_type] => utility
[patent_app_number] => 15/544835
[patent_app_country] => US
[patent_app_date] => 2016-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 35894
[patent_no_of_claims] => 101
[patent_no_of_ind_claims] => 48
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544835
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/544835 | METHODS AND KITS FOR ANALYSIS OF HMGB1 ISOFORMS | Jan 18, 2016 | Abandoned |
Array
(
[id] => 12387834
[patent_doc_number] => 09963517
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-05-08
[patent_title] => Isoform specific anti-HER4 antibodies
[patent_app_type] => utility
[patent_app_number] => 14/946318
[patent_app_country] => US
[patent_app_date] => 2015-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 16
[patent_no_of_words] => 41277
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14946318
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/946318 | Isoform specific anti-HER4 antibodies | Nov 18, 2015 | Issued |
Array
(
[id] => 13447163
[patent_doc_number] => 20180275124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-27
[patent_title] => Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy
[patent_app_type] => utility
[patent_app_number] => 15/541709
[patent_app_country] => US
[patent_app_date] => 2015-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15541709
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/541709 | Modulators of the function of the core domain of annexins, and uses thereof in autoimmune and/or cancer therapy | Nov 18, 2015 | Pending |
Array
(
[id] => 11969915
[patent_doc_number] => 20170274069
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-28
[patent_title] => 'METHOD FOR THE CANCER TREATMENT AND PREVENTION OF METASTATIC DISEASE'
[patent_app_type] => utility
[patent_app_number] => 15/521855
[patent_app_country] => US
[patent_app_date] => 2015-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 8909
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15521855
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/521855 | METHOD FOR THE CANCER TREATMENT AND PREVENTION OF METASTATIC DISEASE | Oct 25, 2015 | Abandoned |
Array
(
[id] => 11943313
[patent_doc_number] => 20170247464
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-31
[patent_title] => 'Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases'
[patent_app_type] => utility
[patent_app_number] => 15/518803
[patent_app_country] => US
[patent_app_date] => 2015-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 11464
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518803
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/518803 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | Oct 20, 2015 | Abandoned |
Array
(
[id] => 10678061
[patent_doc_number] => 20160024206
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-28
[patent_title] => 'Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma'
[patent_app_type] => utility
[patent_app_number] => 14/877450
[patent_app_country] => US
[patent_app_date] => 2015-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 5997
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14877450
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/877450 | Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma | Oct 6, 2015 | Abandoned |
Array
(
[id] => 16291325
[patent_doc_number] => 10768167
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-08
[patent_title] => Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 15/514255
[patent_app_country] => US
[patent_app_date] => 2015-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 10642
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514255
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/514255 | Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer | Sep 24, 2015 | Issued |
Array
(
[id] => 11994288
[patent_doc_number] => 20170298444
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-19
[patent_title] => 'METHODS FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/514152
[patent_app_country] => US
[patent_app_date] => 2015-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 56
[patent_no_of_words] => 12192
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514152
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/514152 | METHODS FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER | Sep 23, 2015 | Abandoned |
Array
(
[id] => 11994205
[patent_doc_number] => 20170298360
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-19
[patent_title] => 'LATS AND BREAST CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/513935
[patent_app_country] => US
[patent_app_date] => 2015-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 26296
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513935
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/513935 | LATS AND BREAST CANCER | Sep 22, 2015 | Abandoned |
Array
(
[id] => 14171713
[patent_doc_number] => 10259852
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-16
[patent_title] => Conjugate comprising P21 protein for the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 14/861923
[patent_app_country] => US
[patent_app_date] => 2015-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 5460
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14861923
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/861923 | Conjugate comprising P21 protein for the treatment of cancer | Sep 21, 2015 | Issued |
Array
(
[id] => 10730947
[patent_doc_number] => 20160077098
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-03-17
[patent_title] => 'RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS'
[patent_app_type] => utility
[patent_app_number] => 14/853254
[patent_app_country] => US
[patent_app_date] => 2015-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 2151
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14853254
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/853254 | RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS | Sep 13, 2015 | Abandoned |
Array
(
[id] => 11943295
[patent_doc_number] => 20170247446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-31
[patent_title] => 'TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 15/508036
[patent_app_country] => US
[patent_app_date] => 2015-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 39
[patent_no_of_words] => 13793
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15508036
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/508036 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES | Sep 9, 2015 | Abandoned |